BCM
IMVT icon

Bayesian Capital Management’s Immunovant IMVT Stock Holding History

Bayesian Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,976
Closed -$209K – 323
2025
Q3 		$209K Buy
+12,976
New +$210K 0.04% 454

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Bayesian Capital Management's IMVT Position: Q4 2025 in Review

Bayesian Capital Management sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 12,976 shares — an estimated $209K sold.

Bayesian Capital Management first reported a position in IMVT in Q3 2025 and held it in 1 quarter. The position peaked at $209K in Q3 2025. 197 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • Bayesian Capital Management reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 12,976 Immunovant shares in Q4 2025, an estimated $209K.
  • Bayesian Capital Management first reported a position in Immunovant in Q3 2025 and held it in 1 quarter.
  • Bayesian Capital Management's Immunovant position peaked at $209K in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.